Pharmacotherapy for Treatment-Resistant Obsessive-Compulsive Disorder

Pharmacotherapy for Treatment-Resistant Obsessive-Compulsive Disorder

Obsessive-compulsive disorder (OCD) is a disabling illness affecting approximately 2%-3% individuals worldwide that is marked by recurrent, distressing intrusive thoughts (obsessions) and repetitive behaviors (compulsions).1,2 The underlying pathophysiology is incompletely understood, but OCD symptoms are thought to emerge partly from aberrant functionality in cortico-striato-thalamo-cortical neural circuits.3 Though OCD is a major cause of functional disability and impairment,4 the only medications currently approved by the US Food and Drug Administration (FDA) are serotonin reuptake inhibitors (SRIs, ie, the selective SRIs [SSRIs] and clomipramine).5 Extensive evidence supports that SRIs are effective for treating OCD symptoms, and with a favorable side effect profile relative to clomipramine, SSRIs are currently the first-line pharmacotherapy.6 However, around half of patients will respond incompletely to SSRIs,7 and at least 8 weeks of sustained treatment are typically needed before meaningful clinical improvement is seen.6 SSRI treatment is associated with dose-dependent side effects including gastrointestinal upset and sexual dysfunction, which may be particularly problematic given that patients with OCD tend to require treatment with higher doses to achieve symptomatic relief compared to those with anxiety and depressive disorders.8

When patients do not respond to or cannot tolerate SSRIs, the evidence supports several next steps. Here, I briefly review options for pharmacologic management of treatment-resistant OCD, summarizing the evidence supporting each. What constitutes “responsiveness” to OCD treatment remains controversial, though improvement from baseline of 25%-35% on the Yale-Brown Obsessive Compulsive Scale is a commonly used definition. Experts similarly disagree on the definition of “treatment resistance,” but have generally quantified it based on the number of failed treatment trials.9 A comprehensive review of this topic, including a review of psychotherapeutic and somatic treatment approaches, is beyond the scope of this article; for more detailed discussions, see references 6, 9, 10, and 11.

Medication Options for Treatment-Resistant OCD

Optimize dose and trial duration. When SSRI treatment produces little response, optimizing the dose is a reasonable first step. Doses exceeding the typical maximum set by manufacturers have been shown to be effective, and the current American Psychiatric Association practice guidelines recommend occasional prescribing of doses as high as escitalopram 60 mg/d, fluoxetine 120 mg/d, fluvoxamine 450 mg/d, paroxetine 100 mg/d, and sertraline 400 mg/d.5 Whereas high-dose SSRIs have been linked to increased side effect burden without increased efficacy for major depressive disorder (MDD), a 2010 meta-analysis found that for patients with OCD, higher SSRI doses were associated with greater efficacy than low or medium doses.8 For example, in a trial of nonresponders to sertraline 200 mg/d, dose titration up to 400 mg/d led to greater symptomatic improvement and similar tolerability compared to maintaining the original dose.10 However, higher SSRI doses are also linked to increased rates of treatment discontinuation due to adverse effects (such as initial gastrointestinal upset or sexual side effects), making careful monitoring for side effects essential.8 Among the SSRIs, citalopram in particular is associated with QT interval prolongation. The FDA now recommends avoiding doses greater than 40 mg/d (and 20 mg/d in elderly patients), which makes citalopram a potentially problematic choice for treating OCD given that doses of up to 120 mg may be required to achieve clinical efficacy. It is less clear whether escitalopram, a therapeutically active enantiomer of citalopram, can prolong QT interval, but nonetheless at doses above the FDA maximum this agent should be used carefully. Electrocardiographic (ECG) monitoring may be required in elderly individuals or those with a cardiac history when using citalopram or escitalopram at any dose.9

Compared to MDD, longer periods of SSRI monotherapy are often required before OCD symptoms respond, leading experts to recommend SSRI trials lasting at least 8-12 weeks (and at least 4-6 weeks at the maximum tolerable dose).5,11 There is no evidence that plasma SSRI levels correlate with OCD treatment efficacy, though they may help to confirm adherence.12

Switch to a different agent. If SSRI response is insufficient despite a trial of adequate dose and duration, switching to an alternative agent is a valid strategy. Options include another SSRI, a serotonin-norepinephrine reuptake inhibitor (SNRI), or clomipramine, with the strongest evidence favoring an additional SSRI trial.6,11 Controlled trials of the SNRIs venlafaxine and duloxetine suggest that both may have some efficacy for treating OCD symptoms, though results were mixed.6,9 There remains a dearth of trials investigating the effects of SNRIs.13 Given results from a prior trial which suggested that augmenting fluoxetine with buspirone (a 5-HT1A agonist) may have some benefit for treatment-resistant OCD, newer serotonergic drugs with 5-HT1A activity such as vortioxetine and vilazodone could theoretically be useful.11 However, the data here are even scarcer. Two case reports14,15 describe successful treatment of refractory OCD with vortioxetine (as monotherapy in one case, combined with aripiprazole in another), while the effects of vilazodone in OCD have yet to be documented at all.

Clomipramine, a tricyclic antidepressant that inhibits serotonin reuptake and binds several other receptor targets, was the first agent to show efficacy in treating OCD. Meta-analyses suggest that clomipramine may be more efficacious than SSRIs.9,11 However, more recent head-to-head trials comparing clomipramine to SSRIs have challenged the idea that clomipramine is truly superior. Moreover, compared to SSRIs, clomipramine is associated with greater side effect burden, including anticholinergic effects (eg, dry mouth, constipation), antihistaminergic effects (eg, sedation, weight gain), anti-alpha-adrenergic effects (eg, hypotension), arrhythmogenic potential (necessitating ECG monitoring), and reduction of the seizure threshold. To reduce the risk for toxicity, clomipramine doses exceeding the FDA maximum of 250 mg should be avoided, and plasma levels should be obtained with the goal of keeping combined levels of clomipramine and its metabolite desmethylclomipramine below 500 ng/mL.5 Considering these challenges, SSRIs remain the first-line agents of choice.

Augment with another medication. When monotherapy does not yield an adequate response, a reasonable next step is to treat with an adjunct medication. Antipsychotic augmentation is supported by the most and highest-quality evidence. Though several different antipsychotics have been studied, a recent meta-analysis found that risperidone had the greatest efficacy,16 while another also found comparable efficacy for aripiprazole.17 Low antipsychotic doses (eg, risperidone up to 3 mg/d, aripiprazole up to 15 mg/d) are recommended given their associated adverse effects, which include weight gain, metabolic syndrome, and tardive dyskinesia (the last of which occurs less frequently with atypical than with typical antipsychotics).6,9,11,18 Approximately one third of treatment-resistant patients with OCD will respond to antipsychotic augmentation; this rate may be somewhat higher in patients with co-occurring motor tics or Tourette syndrome.5,19

Recent evidence of abnormal glutamate neurotransmission in OCD generated a series of trials evaluating glutamate modulators as augmentation agents for treatment-resistant OCD. N-acetylcysteine (NAC) has the greatest body of support. Of 5 randomized, placebo-controlled trials in which it was added to SSRI monotherapy, 3 showed greater efficacy for reducing OCD symptoms compared to placebo.6 NAC between 600 mg/d to 3,000 mg/d was delivered in the above trials, typically in divided doses. It should be noted that NAC is not currently regulated by the FDA. There are not currently enough data to recommend any commercially available NAC brand over another, though 600 mg effervescent capsules were used in the above trials and in several case reports. Randomized, double-blind, placebo-controlled trials of the glutamate modulators lamotrigine (2 trials, up to 100 mg/d), topiramate (3 trials, up to 400 mg/d), riluzole (3 trials, up to 100 mg/d), memantine (3 trials up to 20 mg/d), and intravenous ketamine (1 trial, single dose of 0.5 mg/kg) have all yielded preliminary evidence of efficacy when added to SRIs in patients with treatment-resistant OCD.6,11,20 Smaller open-label studies also support memantine (2 trials) and intravenous ketamine (1 trial) augmentation of SSRIs.21 To date, only case reports describe the effects of intranasal ketamine on OCD symptoms.22,23

Though beyond the scope of this review, evidence supports the efficacy of psychotherapy and somatic treatments as well. Cognitive behavioral therapy is a first-line treatment for OCD and an alternative to SSRIs. CBT can also effectively augment SSRI monotherapy in patients with treatment-resistant OCD, with a recent trial showing larger effect sizes for CBT compared to risperidone augmentation.24 There is evidence supporting the use of repetitive transcranial magnetic stimulation (rTMS) as well.25,26 Surgical options, reserved for the most severe treatment-refractory cases, include deep brain stimulation.27

Conclusion and Future Directions

SSRIs remain the first-line medications for treating OCD. When SSRI treatment fails to control symptoms, the current literature supports the following algorithm: First, optimize the SSRI dose, and ensure an adequate trial length, checking plasma SSRI levels to confirm adherence if appropriate. Second, switch to an alternative agent (initially another SSRI or clomipramine, after which an SNRI could be tried). Third, augment with an additional medication (eg, an antipsychotic or glutamate modulator). ERP and somatic treatments (eg, rTMS and in extreme cases, neurosurgery) should also be considered and can effectively be combined with medications.

Though the evidence base favoring the above strategy is strongest, results from small studies are beginning to reveal possible new medication approaches. For example, in 49 treatment-naive patients with OCD, mirtazapine (an α2-adrenergic receptor antagonist) accelerated the initial treatment response when added to citalopram, though it did not improve overall efficacy.11 Two small studies suggested possible benefits from stimulants, including d-amphetamine and, interestingly, caffeine (which one trial included as an active placebo), though these results need replication.9 Anti-inflammatories have also garnered interest given hypothesized associations between OCD symptoms and inflammatory or autoimmune abnormalities. Results from small trials augmenting fluvoxamine with celecoxib (a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-2) and minocycline (a tetracycline-derived antibiotic that may also have glutamate-modulating and anti-inflammatory properties) were promising, though problematic design aspects (eg, suboptimal fluvoxamine doses) limit their generalizability.28

There remains an urgent need for more effective, faster-working, and more acceptable medications to help individuals with OCD achieve wellness. To that end, researchers are investigating several novel pharmacotherapies. According to the ClinicalTrials.gov database, agents tested in ongoing or recently completed trials include tolcapone, BHV-4157 (troriluzole, a riluzole precursor), rapastinel, probiotics (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175), psilocybin (2 trials), rituximab, nitrous oxide, ketamine, vitamin C, d-cycloserine, nabilone, cannabis, and ondansetron. Testing these agents, which span a variety of classes, may help to identify novel pharmacologic targets and yield new treatments for patients who suffer from OCD.

Published online: September 8, 2020.

Potential conflicts of interest: The author declares no conflict of interest.

Funding/support: This work was supported by the National Institute of Mental Health through a Loan Repayment Award (L30MH120715) and T32 Training Grant in Mood, Anxiety and Related Disorders (T32MH15144) to Dr Kayser.

Acknowledgments: For their assistance in preparing this work, the author acknowledges H. Blair Simpson, MD, PhD, and the research team at the Columbia Center for OCD and Related Disorders.

REFERENCES

1.Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602. PubMed CrossRef

2.American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders. Fifth Edition. Washington, DC: American Psychiatric Association; 2013.

3.Milad MR, Rauch SL. Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways. Trends Cogn Sci. 2012;16(1):43-51. PubMed CrossRef

4.Hollander E, Rowland C, Stein DJ, et al. A pharmaco-economic and quality of life study of obsessive compulsive disorder. Psychopharmacol Bull. 1995;31:526.

5.Koran LM, Hanna GL, Hollander E, et al; American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007;164(7 suppl):5-53. PubMed

6.Stein DJ, Costa DLC, Lochner C, et al. Obsessive-compulsive disorder. Nat Rev Dis Primers. 2019;5(1):52. PubMed CrossRef

7.Bloch MH, Green C, Kichuk SA, et al. Long-term outcome in adults with obsessive-compulsive disorder. Depress Anxiety. 2013;30(8):716-722. PubMed CrossRef

8.Bloch MH, McGuire J, Landeros-Weisenberger A, et al. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry. 2010;15(8):850-855. PubMed CrossRef

9.Fineberg NA, Reghunandanan S, Simpson HB, et al; Accreditation Task Force of the Canadian Institute for Obsessive Compulsive Disorders. Obsessive-compulsive disorder (OCD): practical strategies for pharmacological and somatic treatment in adults. Psychiatry Res. 2015;227(1):114-125. PubMed CrossRef

10.Ninan PT, Koran LM, Kiev A, et al. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry. 2006;67(1):15-22. PubMed CrossRef

11.Pittenger C, Bloch MH. Pharmacological treatment of obsessive-compulsive disorder. Psychiatr Clin North Am. 2014;37(3):375-391. PubMed CrossRef

12.Beaulieu AM, Tabasky E, Osser DN. The psychopharmacology algorithm project at the Harvard South Shore Program: an algorithm for adults with obsessive-compulsive disorder. Psychiatry Res. 2019;281:112583. PubMed CrossRef

13.Pizarro M, Fontenelle LF, Paravidino DC, et al. An updated review of antidepressants with marked serotonergic effects in obsessive-compulsive disorder. Expert Opin Pharmacother. 2014;15(10):1391-1401. PubMed CrossRef

14.Naguy A, Khraibut B, Al-Khadhari S. Successful vortioxetine monotherapy for an adolescent with treatment-resistant obsessive-compulsive disorder. Am J Ther. 2019;26(6):e797-e799. PubMed

15.De Berardis D, Olivieri L, Nappi F, et al. Vortioxetine and aripiprazole combination in treatment-resistant obsessive-compulsive disorder: a case report. J Clin Psychopharmacol. 2017;37(6):732-734. PubMed

16.Dold M, Aigner M, Lanzenberger R, et al. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol. 2013;16(3):557-574. PubMed CrossRef

17.Albert U, Carmassi C, Cosci F, et al. Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review. Int Clin Psychopharmacol. 2016;31(5):249-258. PubMed CrossRef

18.Carbon M, Kane JM, Leucht S, et al. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018;17(3):330-340. PubMed CrossRef

19.Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11(7):622-632. PubMed CrossRef

20.Sheshachala K, Narayanaswamy JC. Glutamatergic augmentation strategies in obsessive-compulsive disorder. Indian J Psychiatry. 2019;61(suppl 1):S58-S65. PubMed CrossRef

21.Kishi T, Matsuda Y, Iwata N. Combination therapy of serotonin reuptake inhibitors and memantine for obsessive- compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. J Alzheimers Dis. 2018;64(1):43-48. PubMed CrossRef

22.Adams TG, Bloch MH, Pittenger C. Intranasal ketamine and cognitive-behavioral therapy for treatment-refractory obsessive-compulsive disorder. J Clin Psychopharmacol. 2017;37(2):269-271. PubMed CrossRef

23.Rodriguez CI, Lapidus KAB, Zwerling J, et al. Challenges in testing intranasal ketamine in obsessive-compulsive disorder. J Clin Psychiatry. 2017;78(4):466-467. PubMed CrossRef

24.Simpson HB, Foa EB, Liebowitz MR, et al. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry. 2013;70(11):1190-1199. PubMed CrossRef

25.Lusicic A, Schruers KRJ, Pallanti S, et al. Transcranial magnetic stimulation in the treatment of obsessive-compulsive disorder: current perspectives. Neuropsychiatr Dis Treat. 2018;14:1721-1736. PubMed CrossRef

26.Carmi L, Tendler A, Bystritsky A, et al. Efficacy and safety of deep transcranial magnetic stimulation for obsessive-compulsive disorder: a prospective multicenter randomized double-blind placebo-controlled trial. Am J Psychiatry. 2019;176(11):931-938. PubMed CrossRef

27.Dougherty DD, Brennan BP, Stewart SE, et al. Neuroscientifically informed formulation and treatment planning for patients with obsessive-compulsive disorder: a review. JAMA Psychiatry. 2018;75(10):1081-1087. PubMed CrossRef

28.Grassi G, Pallanti S. Current and up-and-coming pharmacotherapy for obsessive-compulsive disorder in adults. Expert Opin Pharmacother. 2018;19(14):1541-1550. PubMed CrossRef

aDepartment of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York, New York

bResearch Foundation for Mental Hygiene, New York State Psychiatric Institute, New York, New York

*Corresponding author: Reilly R. Kayser, MD, 1051 Riverside Dr, 3100 Ste, New York, NY 10032 ([email protected]).

J Clin Psychiatry 2020;81(5):19ac13182

To cite: Kayser RR. Pharmacotherapy for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2020;81(5):19ac13182.

To share: https://doi.org/10.4088/JCP.19ac13182

© Copyright 2020 Physicians Postgraduate Press, Inc.